Open AccessExtended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial
Author(s) -
JanStephan Sanders,
Anoek A. E. de Joode,
Ruud G. DeSevaux,
Jan Broekroelofs,
Alexandre E. Voskuyl,
Pieter van Paassen,
Cees G. M. Kallenberg,
Jan Willem Cohen Tervaert,
Coen A. Stegeman
Publication year - 2016
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfw211
Subject(s) - azathioprine , medicine , maintenance therapy , gastroenterology , anti neutrophil cytoplasmic antibody , microscopic polyangiitis , vasculitis , cyclophosphamide , regimen , proteinase 3 , immunology , chemotherapy , disease
Cytoplasmic anti-neutrophil cytoplasmic antibody (C-ANCA) positivity at remission has been associated with an increased relapse rate in patients with proteinase 3 anti-neutrophil cytoplasmic antibody-associated vasculitis (PR3-AAV) after a switch to azathioprine maintenance therapy. We therefore hypothesized that extended azathioprine maintenance therapy could reduce the incidence of relapse in this setting.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom